1
William L Hunter, David M Gravett, Philip M Toleikis, Arpita Maiti, Pierre E Signore, Richard T Liggins, Dechi Guan: Medical implants and fibrosis-inducing agents. Angiotech International, Seed IP Law Group PLLC, January 23, 2007: US07166570 (230 worldwide citation)

Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.


2
John C Lee, Lee Chuan C Yeh: Compositions and therapeutic methods using morphogenic proteins and stimulatory factors. Stryker Corporation, James F Haley, Barbara A Ruskin, Fish & Neave, September 7, 1999: US05948428 (218 worldwide citation)

The present invention provides pharmaceutical compositions comprising a morphogenic protein stimulatory factor (MPSF) for improving the tissue inductive activity of morphogenic proteins, particularly those belonging to the BMP protein family. Methods for improving the tissue inductive activity of a ...


3
Marc Hendriks, Michel Verhoeven, Patrick Cahalan, Raymond Zeeman, Piet Dijkstra, Jan Feijen: Process for making a bioprosthetic device and implants produced therefrom. Medtronic, Thomas F Woods, Michael J Jaro, Harold Patton, September 12, 2000: US06117979 (209 worldwide citation)

Bioprosthetic devices made of collagen-based material having collagen amine groups and collagen carboxyl groups are provided as well as methods for their formation. The methods comprise combining an epoxy functionalized crosslinking agent with the collagen-based material in an aqueous medium at an a ...


4
Hunziker Ernst B: Kits and compositions for the treatment and repair of defects or lesions in cartilage or bone.. Shaw Robert F, March 10, 1993: EP0530804-A1 (187 worldwide citation)

Kits and compositions are provided for the treatment and repair of defects in the cartilage or bone of humans and other animals as in full-thickness defects in joints. A matrix having pores large enough to allow cells to populate the matrix and to form blood vessels is used to fill the defect in bon ...


5
Peter S Linsley, Jeffrey A Ledbetter, Nitin K Damle, William Brady: Chimeric CTLA4 receptor and methods for its use. Bristol Myers Squibb Co, Merchant Gould Smith Edell Welter & Schmidt, July 18, 1995: US05434131 (153 worldwide citation)

The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the so ...


6
Brian Johnstone, Jung Yoo: In vitro chondrogenic induction of human mesenchymal stem cells. Case Western Reserve University, Elliot M Olstein, Raina Semionow, June 1, 1999: US05908784 (128 worldwide citation)

Disclosed are a composition of chemically defined components which support the in vitro chondrogenesis of mesenchymal progenitor cells, a method for in vitro chondrogenic induction of such progenitor cells and a method of forming human chondrocytes in vitro from such progenitor cells.


7
William F McKay: Drug depot implant designs. June 1, 2010: US07727954 (124 worldwide citation)

The present invention relates to novel drug depot implant designs for optimal delivery of therapeutic agents to subjects. The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by targeted delivery of one or more therapeutic agents to in ...


8
Edwardson Peter Andrew David, Fairbrother John Esam, Gardner Ronald Stephen, Hollingsbee Derek Andrew, Cederholm Williams Stuart Anth: Fibrin sealant compositions and method for utilizing same.. Squibb & Sons, April 13, 1994: EP0592242-A1 (117 worldwide citation)

The subject invention relates to fibrin sealants. More specifically, the subject invention relates to the use of a fibrin sealant wherein a composition comprising fibrin monomer or a composition comprising noncrosslinked fibrin is utilized as a component of the fibrin sealant.


9
Wallach David, Engelmann Hartmut, Aderka Dan, Novick Daniela, Rubinstein Menachem: Tumor necrosis factor binding protein ii, its purification and antibodies thereto.. Yeda Res & Dev, November 22, 1990: EP0398327-A1 (106 worldwide citation)

Tumor Necrosis Factor (TNF) Binding Protein is isolated and substantially purified. It has the ability to inhibit the cytotoxic effect of TNF and/or to maintain its prolonged beneficial effects. TNF Binding Protein II and salts, functional derivatives, precursors and active fractions thereof can be ...


10
William L Hunter, Philip M Toleikis, David M Gravett, Rui Avelar, Dechi Guan: Compositions and methods for treating diverticular disease. Angiotech International, Seed IP Law Group PLLC, July 10, 2007: US07241736 (105 worldwide citation)

Agents, compositions, and implants are provided herein for treating diverticular disease (e.g., diverticulosis and diverticulitis). In particular, fibrosis-inducing agents, hemostatic agents, and/or anti-infective agents, or compositions containing one or more of these agents are provided for use in ...